Literature DB >> 1427375

Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients.

I Sobhani1, S Hochlaf, Y Denizot, C Vissuzaine, E Rene, J Benveniste, M M Lewin, M Mignon.   

Abstract

Platelet activating factor (PAF-ACETHER or PAF) and precursors of platelet activating factor were investigated in 26 patients with acute Crohn's disease and in 10 healthy controls. Platelet activating factor, lyso platelet activating factor, and alkyl acyl glycerophosphocholine, were determined in colonic mucosal biopsies in patients with acute Crohn's disease, during prednisolone therapy, and in remission. Biopsy specimens were submitted to histopathology examination and to phospholipid extraction. Platelet activating factor, lyso platelet activating factor, and alkyl acyl glycerophosphocholine were found in patients with acute Crohn's disease and in remission as well as in controls. Whatever the site of the biopsy, the level of platelet activating factor in colonic mucosa was higher (p < 0.01) in Crohn's disease than in controls. There was no correlation between the level of colonic PAF-ACETHER and age, sex, Crohn's disease activity index, and biological parameters in sera. Although concentrations of colonic platelet activating factor content were higher (p < 0.01) when colonic mucosa displayed cell infiltration, they were neither related to the severity nor the type of inflammatory cells. Platelet activating factor decreases with prednisolone therapy and might return to normal concentrations in quiescent patients. Lyso platelet activating factor and alkyl acyl glycerophosphocholine were not significantly higher in Crohn's disease than in controls. These data suggest that platelet activating factor may be involved in the pathogenesis of Crohn's disease and that it could be used as a marker of the mucosal activity of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1427375      PMCID: PMC1379490          DOI: 10.1136/gut.33.9.1220

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  32 in total

Review 1.  Prostaglandins and ulcerative colitis.

Authors:  D S Rampton; C J Hawkey
Journal:  Gut       Date:  1984-12       Impact factor: 23.059

2.  Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate.

Authors:  T M McIntyre; G A Zimmerman; K Satoh; S M Prescott
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

3.  Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists.

Authors:  J L Wallace; G Steel; B J Whittle; V Lagente; B Vargaftig
Journal:  Gastroenterology       Date:  1987-10       Impact factor: 22.682

4.  Potent ulcerogenic actions of platelet-activating factor on the stomach.

Authors:  A C Rosam; J L Wallace; B J Whittle
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

5.  Role of leukotrienes and platelet activating factor in acute gastric mucosal lesions in rats.

Authors:  S J Konturek; T Brzozowski; D Drozdowicz; J Garlicki; G Beck
Journal:  Eur J Pharmacol       Date:  1989-05-19       Impact factor: 4.432

6.  Lipoxygenase products of arachidonic acid modulate biosynthesis of platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by human neutrophils via phospholipase A2.

Authors:  M M Billah; R W Bryant; M I Siegel
Journal:  J Biol Chem       Date:  1985-06-10       Impact factor: 5.157

7.  Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease.

Authors:  A Zifroni; A J Treves; D B Sachar; D Rachmilewitz
Journal:  Gut       Date:  1983-07       Impact factor: 23.059

8.  Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Digestion       Date:  1988       Impact factor: 3.216

9.  Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE.

Authors:  J M Mencia-Huerta; R A Lewis; E Razin; K F Austen
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

10.  Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor.

Authors:  J Benveniste; P M Henson; C G Cochrane
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  20 in total

1.  Correlation of desensitisation of platelet activating factor (PAF) receptors with intensity of inflammation and intestinal PAF content during experimental ileitis in guinea pig.

Authors:  O Jeanneton; M Delvaux; Y Langlois; P Le Bars; J Le Bars; M B Delisle; J Frexinos; L Bueno
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

2.  Quantification of distinct molecular species of platelet activating factor in ulcerative colitis.

Authors:  E Thyssen; J Turk; A Bohrer; W F Stenson
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

Review 3.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer.

Authors:  Lei Sun; Zhen He; Jia Ke; Senmao Li; Xianrui Wu; Lei Lian; Xiaowen He; Xiaosheng He; Jiancong Hu; Yifeng Zou; Xiaojian Wu; Ping Lan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Platelet activating factor and Crohn's disease.

Authors:  Y Denizot; S Chaussade
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis.

Authors:  D Camuesco; M E Rodríguez-Cabezas; N Garrido-Mesa; M Cueto-Sola; E Bailón; M Comalada; B Arribas; M Merlos; D Balsa; A Zarzuelo; G Janer; J Xaus; J Román; J Gálvez
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin.

Authors:  I Sobhani; Y Denizot; S Hochlaf; D Rigaud; J Vatier; J Benveniste; M J Lewin; M Mignon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

8.  Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent.

Authors:  Alip Borthakur; Sumit Bhattacharyya; Waddah A Alrefai; Joanne K Tobacman; Krishnamurthy Ramaswamy; Pradeep K Dudeja
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

Review 9.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

10.  Platelet-activating factor-induced chloride channel activation is associated with intracellular acidosis and apoptosis of intestinal epithelial cells.

Authors:  Erika C Claud; Jing Lu; Xue Qing Wang; Mark Abe; Elaine O Petrof; Jun Sun; Deborah J Nelson; Jeremy Marks; Tamas Jilling
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-03-13       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.